Literature DB >> 9219142

The costs of drug abuse consequences: a summary of research findings.

M T French1, R F Martin.   

Abstract

The purpose of this article is to provide researchers, clinicians, and policymakers with a common source of published cost estimates for drug abuse consequences. Across the broad range of potential complications associated with drug abuse, some of the cost elements are specific and directly related to drug abuse per se (e.g., drug treatment costs), while other items may be related to drug abuse (e.g., typical emergency room cost). The results presented here are based on a review of completed and ongoing studies, which include published papers, monographs, conference presentations, working papers, reports, insurance company records, newsletters, and expert judgment. Whenever possible, we report an average cost estimate and the range of available estimates. Each cost element is normalized to 1994 dollars. The results are organized by type of cost and are presented in tabular format so that the findings can be easily understood and used.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9219142     DOI: 10.1016/s0740-5472(96)00128-6

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  13 in total

1.  Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"?

Authors:  Susan L Ettner; David Huang; Elizabeth Evans; Danielle Rose Ash; Mary Hardy; Mickel Jourabchi; Yih-Ing Hser
Journal:  Health Serv Res       Date:  2006-02       Impact factor: 3.402

2.  Monetary conversion factors for economic evaluations of substance use disorders.

Authors:  Kathryn McCollister; Xuan Yang; Bisma Sayed; Michael T French; Jared A Leff; Bruce R Schackman
Journal:  J Subst Abuse Treat       Date:  2017-07-18

3.  The costs of crime associated with stimulant use in a Canadian setting.

Authors:  Benjamin Enns; Emanuel Krebs; Kora DeBeck; Kanna Hayashi; M-J Milloy; Lindsey Richardson; Evan Wood; Bohdan Nosyk
Journal:  Drug Alcohol Depend       Date:  2017-09-14       Impact factor: 4.492

4.  The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.

Authors:  Gary A Zarkin; Jeremy W Bray; Arnie Aldridge; Michael Mills; Ron A Cisler; David Couper; James R McKay; Stephanie O'Malley
Journal:  Med Care       Date:  2010-05       Impact factor: 2.983

5.  Economic analysis of a multi-site prevention program: assessment of program costs and characterizing site-level variability.

Authors:  Phaedra S Corso; Justin B Ingels; Steven M Kogan; E Michael Foster; Yi-Fu Chen; Gene H Brody
Journal:  Prev Sci       Date:  2013-10

6.  Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model.

Authors:  Gary A Zarkin; Alexander J Cowell; Katherine A Hicks; Michael J Mills; Steven Belenko; Laura J Dunlap; Kimberly A Houser; Vince Keyes
Journal:  Health Econ       Date:  2011-04-19       Impact factor: 3.046

7.  Interim versus standard methadone treatment: a benefit-cost analysis.

Authors:  Robert P Schwartz; Pierre K Alexandre; Sharon M Kelly; Kevin E O'Grady; Jan Gryczynski; Jerome H Jaffe
Journal:  J Subst Abuse Treat       Date:  2013-10-14

Review 8.  Economic evaluation of interventions to treat opiate dependence : a review of the evidence.

Authors:  Christopher M Doran
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Benefit-cost analysis of SBIRT interventions for substance using patients in emergency departments.

Authors:  Brady P Horn; Cameron Crandall; Alyssa Forcehimes; Michael T French; Michael Bogenschutz
Journal:  J Subst Abuse Treat       Date:  2017-05-04

10.  Cost and Return on Investment of a Work-Family Intervention in the Extended Care Industry: Evidence From the Work, Family, and Health Network.

Authors:  William N Dowd; Jeremy W Bray; Carolina Barbosa; Krista Brockwood; David J Kaiser; Michael J Mills; David A Hurtado; Brad Wipfli
Journal:  J Occup Environ Med       Date:  2017-10       Impact factor: 2.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.